FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2095291804> ?p ?o ?g. }

• W2095291804 endingPage "8" @default.
• W2095291804 startingPage "1" @default.
• W2095291804 abstract "Although antibiotic treatment for Lyme disease is effective in the majority of cases, especially during the early phase of the disease, a minority of patients suffer from post-treatment Lyme disease syndrome (PTLDS). It is unclear what mechanisms drive this problem, and although slow or ineffective killing of Borrelia burgdorferi has been suggested as an explanation, there is a lack of evidence that viable organisms are present in PTLDS. Although not a clinical surrogate, insight may be gained by examining stationary-phase in vitro Borrelia burgdorferi persisters that survive treatment with the antibiotics doxycycline and amoxicillin. To identify drug candidates that can eliminate B. burgdorferi persisters more effectively, we screened an Food and Drug Administration (FDA)-approved drug library consisting of 1524 compounds against stationary-phase B. burgdorferi by using a newly developed high throughput SYBR Green I/propidium iodide (PI) assay. We identified 165 agents approved for use in other disease conditions that had more activity than doxycycline and amoxicillin against B. burgdorferi persisters. The top 27 drug candidates from the 165 hits were confirmed to have higher anti-persister activity than the current frontline antibiotics. Among the top 27 confirmed drug candidates from the 165 hits, daptomycin, clofazimine, carbomycin, sulfa drugs (e.g., sulfamethoxazole), and certain cephalosporins (e.g. cefoperazone) had the highest anti-persister activity. In addition, some drug candidates, such as daptomycin and clofazimine (which had the highest activity against non-growing persisters), had relatively poor activity or a high minimal inhibitory concentration (MIC) against growing B. burgdorferi. Our findings may have implications for the development of a more effective treatment for Lyme disease and for the relief of long-term symptoms that afflict some Lyme disease patients." @default.
• W2095291804 created "2016-06-24" @default.
• W2095291804 creator A5006923052 @default.
• W2095291804 creator A5023112797 @default.
• W2095291804 creator A5027586359 @default.
• W2095291804 creator A5031006470 @default.
• W2095291804 creator A5036477294 @default.
• W2095291804 creator A5068080767 @default.
• W2095291804 creator A5082924617 @default.
• W2095291804 date "2014-01-01" @default.
• W2095291804 modified "2023-10-06" @default.
• W2095291804 title "Identification of novel activity against<i>Borrelia burgdorferi</i>persisters using an FDA approved drug library" @default.
• W2095291804 cites W1656338199 @default.
• W2095291804 cites W1965530674 @default.
• W2095291804 cites W1973838773 @default.
• W2095291804 cites W1980984820 @default.
• W2095291804 cites W1986519128 @default.
• W2095291804 cites W1993369443 @default.
• W2095291804 cites W1995024953 @default.
• W2095291804 cites W1999311978 @default.
• W2095291804 cites W2008731781 @default.
• W2095291804 cites W2013636685 @default.
• W2095291804 cites W2015096711 @default.
• W2095291804 cites W2018340232 @default.
• W2095291804 cites W2029524347 @default.
• W2095291804 cites W2035712906 @default.
• W2095291804 cites W2036571922 @default.
• W2095291804 cites W2061126046 @default.
• W2095291804 cites W2061361289 @default.
• W2095291804 cites W2063165604 @default.
• W2095291804 cites W2100820660 @default.
• W2095291804 cites W2104720535 @default.
• W2095291804 cites W2106077838 @default.
• W2095291804 cites W2109519899 @default.
• W2095291804 cites W2113063737 @default.
• W2095291804 cites W2125159822 @default.
• W2095291804 cites W2126060212 @default.
• W2095291804 cites W2130803530 @default.
• W2095291804 cites W2133866452 @default.
• W2095291804 cites W2136047088 @default.
• W2095291804 cites W2138690106 @default.
• W2095291804 cites W2140716928 @default.
• W2095291804 cites W2143628550 @default.
• W2095291804 cites W2149269977 @default.
• W2095291804 cites W2160839923 @default.
• W2095291804 cites W2163533527 @default.
• W2095291804 cites W2163586341 @default.
• W2095291804 cites W4319429759 @default.
• W2095291804 doi "https://doi.org/10.1038/emi.2014.53" @default.
• W2095291804 hasPubMedCentralId "https://www.ncbi.nlm.nih.gov/pmc/articles/4126181" @default.
• W2095291804 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/26038747" @default.
• W2095291804 hasPublicationYear "2014" @default.
• W2095291804 type Work @default.
• W2095291804 sameAs 2095291804 @default.
• W2095291804 citedByCount "91" @default.
• W2095291804 countsByYear W20952918042014 @default.
• W2095291804 countsByYear W20952918042015 @default.
• W2095291804 countsByYear W20952918042016 @default.
• W2095291804 countsByYear W20952918042017 @default.
• W2095291804 countsByYear W20952918042018 @default.
• W2095291804 countsByYear W20952918042019 @default.
• W2095291804 countsByYear W20952918042020 @default.
• W2095291804 countsByYear W20952918042021 @default.
• W2095291804 countsByYear W20952918042022 @default.
• W2095291804 countsByYear W20952918042023 @default.
• W2095291804 crossrefType "journal-article" @default.
• W2095291804 hasAuthorship W2095291804A5006923052 @default.
• W2095291804 hasAuthorship W2095291804A5023112797 @default.
• W2095291804 hasAuthorship W2095291804A5027586359 @default.
• W2095291804 hasAuthorship W2095291804A5031006470 @default.
• W2095291804 hasAuthorship W2095291804A5036477294 @default.
• W2095291804 hasAuthorship W2095291804A5068080767 @default.
• W2095291804 hasAuthorship W2095291804A5082924617 @default.
• W2095291804 hasBestOaLocation W20952918041 @default.
• W2095291804 hasConcept C159047783 @default.
• W2095291804 hasConcept C159654299 @default.
• W2095291804 hasConcept C203014093 @default.
• W2095291804 hasConcept C2776297342 @default.
• W2095291804 hasConcept C2777179404 @default.
• W2095291804 hasConcept C2777553296 @default.
• W2095291804 hasConcept C2779159148 @default.
• W2095291804 hasConcept C2780035454 @default.
• W2095291804 hasConcept C2780695269 @default.
• W2095291804 hasConcept C501593827 @default.
• W2095291804 hasConcept C71924100 @default.
• W2095291804 hasConcept C86803240 @default.
• W2095291804 hasConcept C89423630 @default.
• W2095291804 hasConcept C98274493 @default.
• W2095291804 hasConceptScore W2095291804C159047783 @default.
• W2095291804 hasConceptScore W2095291804C159654299 @default.
• W2095291804 hasConceptScore W2095291804C203014093 @default.
• W2095291804 hasConceptScore W2095291804C2776297342 @default.
• W2095291804 hasConceptScore W2095291804C2777179404 @default.
• W2095291804 hasConceptScore W2095291804C2777553296 @default.
• W2095291804 hasConceptScore W2095291804C2779159148 @default.
• W2095291804 hasConceptScore W2095291804C2780035454 @default.
• W2095291804 hasConceptScore W2095291804C2780695269 @default.
• W2095291804 hasConceptScore W2095291804C501593827 @default.

• next